Huy T. Nguyen

Huy T. Nguyen

Auto-generated profile, based on publicly available information

Huy T. Nguyen

Center for Biopharmaceuticals & Department of Drug Design and Pharmacology Faculty of Health and Medical Sciences University of Copenhagen Universitetsparken 2 DK-2100 Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2022 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
AAAline D. de Araujo
Aline D. de Araujo
JLJunxian Lim
Junxian Lim
KWKai-Chen Wu
Kai-Chen Wu
HHHuy N. Hoang
Huy N. Hoang
HNHuy T. Nguyen
Huy T. Nguyen
DFDavid P. Fairlie
David P. Fairlie
Cyclic peptides that modulate protein–protein interactions can be valuable therapeutic candidates if they can be delivered intact to their target proteins in cells. Here we systematically compare the effects of different helix-inducing cyclization constraints on the capacity of a macrocyclic peptide component to confer α-helicity, protein-binding affinity, resistance to degradative proteases and cell uptake to a 12-residue peptide fragment of tumor suppressor protein p53. We varied the helix-inducing constraint (hydrocarbon, lactam, aliphatic or aromatic thioether, etc.) and the position of the cyclization linker (i to i + 4 or i to i + 7 bridges) in order to sculpt the macrocyclic size, stabilize its structure, and promote cell uptake. We find that rigidifying the macrocycle leads to higher alpha helicity, target affinity and proteolytic stability to different extents, whereas cell uptake of compounds shown here is mostly driven by hydrophobicity and aromaticity of the macrocycle.

30 March 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
NRNima Rajabi
Nima Rajabi
THTobias N. Hansen
Tobias N. Hansen
ANAlexander Lund Nielsen
Alexander Lund Nielsen
HNHuy T. Nguyen
Huy T. Nguyen
MBMichael Bæk
Michael Bæk
COChristian Olsen
Christian Olsen
Sirtuin 5 (SIRT5) is a protein lysine deacylase enzyme that regulates diverse biology by hydrolyzing ϵ‐N‐carboxyacyllysine posttranslational modifications in the cell. Inhibition of SIRT5 has been linked to potential treatment of several cancers but potent compounds with activity in cells have been lacking. Here we developed mechanism‐based inhibitors that incorporate isosteres of a carboxylic acid residue that is important for high‐affinity binding to the enzyme active site. By masking of the tetrazole moiety of the most potent candidate from our initial SAR study, we achieved potent and cytoselective growth inhibition for the treatment of SIRT5‐dependent leukemic cancer cell lines in culture. Thus, we provide an efficient, cellularly active small molecule that targets SIRT5, which can help elucidate its function and potential as a future drug target. This work shows that masked isosteres of carboxylic acids are viable chemical motifs for the development of inhibitors that target mitochondrial enzymes, which may have applications beyond the sirtuin field.

27 January 2021 in ChemBioChem
Verified
Journal Article
Closed access
PDF file
AAAline D. de Araujo
Aline D. de Araujo
HNHuy T. Nguyen
Huy T. Nguyen
DFDavid P. Fairlie
David P. Fairlie

30 March 2022 in Angewandte Chemie
Verified
Journal Article
Open access
NRNima Rajabi
Nima Rajabi
THTobias N. Hansen
Tobias N. Hansen
ANAlexander Lund Nielsen
Alexander Lund Nielsen
HNHuy T. Nguyen
Huy T. Nguyen
MBMichael Bæk
Michael Bæk
COChristian Olsen
Christian Olsen
Sirtuin 5 (SIRT5) is a protein lysine deacylase enzyme that regulates diverse biology by hydrolyzing ϵ‐N‐carboxyacyllysine posttranslational modifications in the cell. Inhibition of SIRT5 has been linked to potential treatment of several cancers but potent compounds with activity in cells have been lacking. Here we developed mechanism‐based inhibitors that incorporate isosteres of a carboxylic acid residue that is important for high‐affinity binding to the enzyme active site. By masking of the tetrazole moiety of the most potent candidate from our initial SAR study, we achieved potent and cytoselective growth inhibition for the treatment of SIRT5‐dependent leukemic cancer cell lines in culture. Thus, we provide an efficient, cellularly active small molecule that targets SIRT5, which can help elucidate its function and potential as a future drug target. This work shows that masked isosteres of carboxylic acids are viable chemical motifs for the development of inhibitors that target mitochondrial enzymes, which may have applications beyond the sirtuin field.

4 February 2026 in Biochemical Journal
Verified
Journal Article
Open access
JBJessica A. Buchanan
Jessica A. Buchanan
OLOlivia Lavidis
Olivia Lavidis
NSNicholas Shields
Nicholas Shields
KHKatriona Harrison
Katriona Harrison
HNHuy T. Nguyen
Huy T. Nguyen
MSMargaret Sunde
Margaret Sunde
Receptor interacting protein kinase 3 (RIPK3) is a central regulator of necroptosis and a key mediator of inflammatory signalling. Its function is orchestrated through RIP homotypic interaction motif (RHIM)-dependent interactions with other RHIM-containing adapter proteins, forming amyloid-structured necrosomes that trigger kinase activation and subsequently lead to immunogenic cell lysis. Necroptosis eliminates infected or damaged cells and provokes a strong inflammatory response. Dysregulated necroptosis is implicated in chronic inflammatory diseases and associated with ischaemic injury. Despite separate structural elucidation of the isolated RIPK3 kinase domain and the amyloid fibrils formed by the RIPK3 RHIM-containing region, visualising full-length human RIPK3 in live cells remains challenging due to a lack of specific tools. To address this, we employed random non-standard peptide integrated discovery (RaPID) mRNA display to identify cyclic peptides that bind the RHIM-containing region of RIPK3 during its assembly into amyloid fibrils. Three peptides were selected for characterisation and demonstrate utility in visualising RIPK3 in human cells. These peptides represent promising tools for probing RIPK3 localisation and modulating its function.

6 November 2025 in bioRxiv
Verified
Preprint
Open access
JBJessica A. Buchanan
Jessica A. Buchanan
OLOlivia Lavidis
Olivia Lavidis
NSNicholas Shields
Nicholas Shields
KHKatriona Harrison
Katriona Harrison
HNHuy T. Nguyen
Huy T. Nguyen
MSMargaret Sunde
Margaret Sunde
Receptor Interacting Protein Kinase 3 (RIPK3) is a central regulator of necroptosis and a key mediator of inflammatory signaling. Its function is orchestrated through RIP Homotypic Interaction Motif (RHIM)-dependent interactions with other RHIM-containing adapter proteins, forming amyloid-structured necrosomes that trigger kinase activation and subsequently lead to immunogenic cell lysis. Necroptosis eliminates infected or damaged cells and provokes a strong inflammatory response. Dysregulated necroptosis is implicated in chronic inflammatory diseases and associated with ischaemic injury. Despite separate structural elucidation of the isolated RIPK3 kinase domain and the amyloid fibrils formed by the RIPK3 RHIM-containing region, visualizing full-length human RIPK3 in live cells remains challenging due to a lack of specific tools. To address this, we employed Random Non-standard Peptide Integrated Discovery (RaPID) mRNA display to identify cyclic peptides that bind the RHIM-containing region of RIPK3 during its assembly into amyloid fibrils. Three peptides were selected for characterisation and demonstrate utility in visualizing RIPK3 in human cells. These peptides represent promising tools for probing RIPK3 localisation and modulating its function.